Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)

This study has been completed.

First Received: August 30, 2006 Last Updated: July 9, 2008 History of Changes

Sponsored by:	Shaheed Beheshti Medical University
Information provided by:	Shaheed Beheshti Medical University
ClinicalTrials.gov Identifier:	NCT00370786

Purpose

To evaluate the effect of bevacizumab for treatment of non-AMD choroidal neovascularization (CNV); eg:angioid streaks, ocular histoplasmosis, high myopia, idiopathic,etc

Condition	Intervention	Phase
Choroidal Neovascularization	Drug: bevacizumab	Phase III

Drug Information available for: Bevacizumab

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Further study details as provided by Shaheed Beheshti Medical University:

Primary Outcome Measures:

Visual acuity [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

central macular thickness [ Time Frame: 6 months ] [ Designated as safety issue: No ]
leakage in fluorescein angiography [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment:	31
Study Start Date:	November 2005
Study Completion Date:	February 2008
Primary Completion Date:	November 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: bevacizumab

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Cases with subfoveal or juxtafoveal CNV due to a non-AMD related cause.

Exclusion Criteria:

Evidence of AMD

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00370786

Locations

Iran, Islamic Republic of
Hamid Ahmadieh, MD
Tehran, Iran, Islamic Republic of, 16666

Sponsors and Collaborators

Shaheed Beheshti Medical University

Investigators

Principal Investigator:

Hamid Ahmadieh, MD

Ophthalmic Research Center of Shaheed Beheshti Medical University

More Information

No publications provided

Responsible Party:	ophthalmic research center
Study ID Numbers:	8543
Study First Received:	August 30, 2006
Last Updated:	July 9, 2008
ClinicalTrials.gov Identifier:	NCT00370786 History of Changes
Health Authority:	Iran: Ethics Committee

Keywords provided by Shaheed Beheshti Medical University:

Choroidal neovascularization (CNV)
Bevacizumab
Non AMD
High myopia

angioid streaks
Ocular histoplasmosis
Idiopathic

Study placed in the following topic categories:

Eye Diseases
Metaplasia
Choroid Diseases
Histoplasmosis
Macular Degeneration
Myopia, Severe

Bevacizumab
Neovascularization, Pathologic
Myopia
Angiogenesis Inhibitors
Angioid Streaks
Choroidal Neovascularization

Additional relevant MeSH terms:

Uveal Diseases
Antineoplastic Agents
Eye Diseases
Growth Substances
Choroid Diseases
Physiological Effects of Drugs
Bevacizumab
Angiogenesis Inhibitors

Pharmacologic Actions
Choroidal Neovascularization
Pathologic Processes
Therapeutic Uses
Metaplasia
Growth Inhibitors
Neovascularization, Pathologic
Angiogenesis Modulating Agents

ClinicalTrials.gov processed this record on May 07, 2009